Inventor · disambiguated record
Michael Hayden
Also filed as: HAYDEN MICHAEL · HAYDEN MICHAEL R
38 granted patents·75 pending applications·370 citations·filing 1993–2025
97Inventor score
Files withPrilenia Neurotherapeutics Ltd32HAYDEN MICHAEL16UNIV BRITISH COLUMBIA15HAYDEN MICHAEL R9STAGING CONCEPTS INC5
Top patents by PatentIndex Score
113 records- 0195US9006198B2Selective reduction of allelic variantsBENNETT C FRANK·Filed 2011·Granted Apr 14, 2015·36 cites·20 claims
- 0293US6617122B1Process for identifying modulators of ABC1 activityXENON GENETICS INC·Filed 2000·Granted Sep 9, 2003·135 cites·51 claims
- 0391US8679750B2Methods and compositions for the treatment of Huntington'S diseaseHAYDEN MICHAEL·Filed 2009·Granted Mar 25, 2014·26 cites·8 claims
- 0484US11406625B2Method of treating amyotrophic lateral sclerosis with pridopidinePrilenia Neurotherapeutics Ltd·Filed 2020·Granted Aug 9, 2022·2 cites·15 claims
- 0584US10603311B2Use of pridopidine to improve cognitive function and for treating Alzheimer's diseasePrilenia Neurotherapeutics Ltd·Filed 2016·Granted Mar 31, 2020·4 cites·12 claims
- 0684US2024309452A1Selective Reduction of Allelic VariantsIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0783US12102627B2Use of pridopidine for treating rett syndromePrilenia Neurotherapeutics Ltd·Filed 2020·Granted Oct 1, 2024·1 cites·25 claims
- 0881US6987001B2Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agentsUNIV BRITISH COLUMBIA·Filed 2001·Granted Jan 17, 2006·11 cites·11 claims
- 0980US9702007B2Genetic markers predictive of response to glatiramer acetateTCHELET AMIR·Filed 2014·Granted Jul 11, 2017·6 cites·20 claims
- 1078US9157120B2Methods and compositions for the treatment of huntington's diseaseUNIV BRITISH COLUMBIA·Filed 2014·Granted Oct 13, 2015·2 cites·8 claims
- 1178US7971395B1Multipurpose adjustable panel systemSTAGING CONCEPTS INC·Filed 2006·Granted Jul 5, 2011·17 cites·30 claims
- 1278US2025360121A1Pridopidine for treating huntington's diseasePrilenia Neurotherapeutics Ltd·Filed 2025·Application pending·0 cites
- 1376US5849995AMouse model for Huntington's Disease and related DNA sequencesUNIV BRITISH COLUMBIA·Filed 1995·Granted Dec 15, 1998·34 cites·20 claims
- 1474US7816075B2Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2005·Granted Oct 19, 2010·1 cites·7 claims
- 1574US7785886B2Methods and reagents for modulating cholesterol levelsXENON PHARMACEUTICALS INC·Filed 2004·Granted Aug 31, 2010·5 cites·5 claims
- 1674US6814962B1Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to sameAVENTIS PHARMA SA·Filed 2000·Granted Nov 9, 2004·3 cites·15 claims
- 1771US2024398778A1Use of pridopidine for treating rett syndromePrilenia Neurotherapeutics Ltd·Filed 2024·Application pending·0 cites
- 1870US2020377946A1Selective Reduction of Allelic VariantsIONIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1970US2024050423A1Use of pridopidine for the treatment of anxiety and depressionPrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 2067US11000519B2Pridopidine for treating drug induced dyskinesiasPrilenia Neurotherapeutics Ltd·Filed 2019·Granted May 11, 2021·0 cites·20 claims
- 2167US10828308B2Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurineHADASIT MED RES SERVICE·Filed 2018·Granted Nov 10, 2020·1 cites·19 claims
- 2266US2025082619A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2024·Application pending·0 cites
- 2366US2023181548A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 2465US2019117639A1Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's diseaseHAYDEN MICHAEL·Filed 2018·Application pending·0 cites
- 2565US2018369228A1Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's diseaseHAYDEN MICHAEL·Filed 2018·Application pending·0 cites
- 2664US2025235441A1Use of pridopidine for the treatment of anxiety and depressionPrilenia Neurotherapeutics Ltd·Filed 2025·Application pending·0 cites
- 2764US2024148708A1Method of treating amyotrophic lateral sclerosis with pridopidinePrilenia Neurotherapeutics Ltd·Filed 2024·Application pending·0 cites
- 2864US2018250285A1Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's diseaseHAYDEN MICHAEL·Filed 2018·Application pending·0 cites
- 2963US7895792B1Stage system with connectable cornerSTAGING CONCEPTS INC·Filed 2009·Granted Mar 1, 2011·1 cites·14 claims
- 3063US2011104257A1Polymorphisms predictive of platinum-coordinating compound-induced ototoxicityHAYDEN MICHAEL R·Filed 2009·Application pending·0 cites
- 3163US2005163754A1Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to sameUNIV BRITISH COLUMBIA·Filed 2004·Application pending·0 cites
- 3262US10533172B2Allele-specific therapy for huntington disease haplotypesUNIV BRITISH COLUMBIA·Filed 2015·Granted Jan 14, 2020·1 cites·34 claims
- 3362US2018133209A1Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's diseaseHAYDEN MICHAEL·Filed 2017·Application pending·0 cites
- 3462US2017319569A1Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's diseaseHAYDEN MICHAEL·Filed 2017·Application pending·0 cites
- 3562US2023330073A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 3662US2024261273A1Pridopidine and analogs thereof for the treatment of neurodegenerative eye diseasePrilenia Neurotherapeutics Ltd·Filed 2024·Application pending·0 cites
- 3762US2023355595A1Use of pridopidine for treating functional declinePrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 3861US2014088140A1Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's diseaseHAYDEN MICHAEL·Filed 2013·Application pending·0 cites
- 3961US2015209346A1Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's diseaseHAYDEN MICHAEL·Filed 2013·Application pending·0 cites
- 4061US2009257981A1Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to sameUNIV BRITISH COLUMBIA·Filed 2007·Application pending·0 cites
- 4160US12036213B2Pridopidine for treating drug induced dyskinesiasPrilenia Neurotherapeutics Ltd·Filed 2021·Granted Jul 16, 2024·0 cites·29 claims
- 4260US10731160B2Allele-specific therapy for Huntington disease haplotypesUNIV BRITISH COLUMBIA·Filed 2020·Granted Aug 4, 2020·0 cites·24 claims
- 4360US5935675AStage systemSTAGING CONCEPTS INC·Filed 1997·Granted Aug 10, 1999·21 cites·1 claims
- 4460US2014147516A1Polymorphisms predictive of platinum-coordinating compound-induced ototoxicityUNIV BRITISH COLUMBIA·Filed 2013·Application pending·0 cites
- 4560US2018291453A1Selective reduction of allelic variantsIONIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4660US2021220342A1Pridopidine for the treatment of mitochondrial-associated diseases and disorders and endoplasmic reticulum (er) stressPrilenia Neurotherapeutics Ltd·Filed 2021·Application pending·0 cites
- 4759US8957071B2Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitorsGLICKMAN RICHARD·Filed 2008·Granted Feb 17, 2015·1 cites·18 claims
- 4859US2025221972A1Pridopidine for the treatment of mitochondrial-associated diseases and disordersPrilenia Neurotherapeutics Ltd·Filed 2025·Application pending·0 cites
- 4959US2023190724A1Method of treating amyotrophic lateral sclerosis with pridopidinePrilenia Neurotherapeutics Ltd·Filed 2023·Application pending·0 cites
- 5059US2014023726A1Polymorphisms predictive of platinum-coordinating complex induced ototoxicityUNIV BRITISH COLUMBIA·Filed 2013·Application pending·0 cites
Showing the top 50 of 113 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Michael Hayden files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →